A PYMNTS Company

Judge Rules Gilead Must Face Price-Fixing Antitrust Case

By  |  March 4, 2020

Gilead Sciences Inc and other drugmakers must face a proposed class action lawsuit by AIDS activists and consumers alleging they used anticompetitive tactics to keep prices for HIV medications including Truvada artificially high, a federal judge has ruled.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    U.S. District Judge Edward Chen in San Francisco on Tuesday said the lawsuit adequately alleged Gilead violated antitrust laws by striking deals to prevent generic versions of its branded medications from being used in HIV drug “cocktails.”

    Full Content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.